Tekla Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $3.55M | Hold |
504,528
| – | – | 0.14% | 93 |
|
|
2023
Q1 | $4.21M | Sell |
504,528
-168,177
| -25% | -$1.4M | 0.16% | 85 |
|
|
2022
Q4 | $7.72M | Buy |
672,705
+323,135
| +92% | +$3.71M | 0.29% | 64 |
|
|
2022
Q3 | $4.41M | Buy |
349,570
+72,136
| +26% | +$909K | 0.18% | 84 |
|
|
2022
Q2 | $2.94M | Buy |
277,434
+80,809
| +41% | +$855K | 0.12% | 104 |
|
|
2022
Q1 | $3.2M | Buy |
+196,625
| New | +$3.2M | 0.11% | 107 |
|
|
2018
Q1 | – | Sell |
-449,255
| Closed | -$2.21M | – | 189 |
|
|
2017
Q4 | $2.21M | Buy |
449,255
+126,000
| +39% | +$619K | 0.09% | 122 |
|
|
2017
Q3 | $1.69M | Buy |
+323,255
| New | +$1.69M | 0.06% | 126 |
|